Enrichment and molecular characterization of single disseminated tumor cells (DTCs) and proof of circulating tumor cell (CTC)- and DTC-mediated tumorigenicity in vitro and in vivo
Enrichment and molecular characterization of single disseminated tumor cells (DTCs) and proof of circulating tumor cell (CTC)- and DTC-mediated tumorigenicity in vitro and in vivo
批准号:
142420260
负责人:
Professor Dr. Jürgen Weitz
金额:
$0.0万
依托单位国家:
德国
项目类别:
Clinical Research Units
财政年份:
2009
资助国家:
德国
项目状态:
已结题
起止时间:
2008-12-31 至 2018-12-31
中文摘要
点击翻译按钮获取中文摘要
英文摘要
For many years, various attempts have been made to develop techniques enabling to detect and isolate circulating (CTC) or disseminated tumor cells (DTC) from the blood and bone marrow of patients with solid cancer (see review: Pantel K et al., Nat Rev Cancer 2008). Importantly, a recent systematic review and meta-analysis from our group corroborate the potential prognostic relevance of CTC in colorectal cancer (CRC) (Rahbari, Aigner et al., manuscript in preparation). The analysis, however, reveals major inter-study variability, which may be reflected by the fact that these cells constitute a heterogeneous cell pool with partly cancer stem cell (CSC)-like, i. e. cancer-initiating, properties. CSCs constitute a rare tumor fraction which are able to self-renew, to differentiate and to proliferate (Reya T et aL, Nature 2001); following xenotransplantation into immunodeficient mice, these cells re-establish the original tumor s morphology (O Brien CA et al., Nature 2007; Ricci-Vitiani L et al.. Nature 2007). Thus, the focus and aim of this subproject is to better define the phenotypic properties of CTC and DTC. Therefore, we first plan to isolate and then to phenotypically characterize CTC and DTC from patients with CRC with regard to both (i) markers associated with CRC stemness (e. g. GD133 [O Brien CA et al., Nature 2007; Ricci-Vitiani L et al., Nature 2007], CD166 [Dalerba P et al., PNAS 2007], CD44 [Du L et al., Clin Cancer Res 2008]) and (ii) markers involved in epithelial-mesenchymal transition (EMT, e. g. E-cadherin, N-cadherin, vimentin, fibronectin [Mani SA et al., Cell 2008] and Twist [Ansieau S et al.. Cancer Cell 2008; Yang MH et al., Nat Cell Biol 2008; Valdes-Mora F et al., Ann Surg Oncol 2008]). Furthermore, the outgrowth of freshly isolated DTC injected into the renal capsule of immunodeficient mice should serve as a proof for our hypothesis that the CTC and DTC fraction contains cancer stem cells with cancer-initiating capacities. In conclusion, our data should not only reveal new insights into the early steps of metastasis formation, but correlation of our results with the clinical follow-up of the examined patients (see also C-Project) may also help to assess the prognostic relevance of circulating cancer-initiating cells (CIC).
期刊论文(5)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
登录
查看更多内容
配子生成素GGN不同位点突变损伤分子伴侣BIP及HSP90B1功能导致精子形成障碍的发病机理
-
批准号:82371616
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:姚晨成
-
依托单位:
MYRF/SLC7A11调控施万细胞铁死亡在三叉神经痛脱髓鞘病变中的作用和分子机制研究
-
批准号:82370981
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:陈敏洁
-
依托单位:
PET/MR多模态分子影像在阿尔茨海默病炎症机制中的研究
-
批准号:82372073
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:张淼
-
依托单位:
GREB1突变介导雌激素受体信号通路导致深部浸润型子宫内膜异位症的分子遗传机制研究
-
批准号:82371652
-
项目类别:面上项目
-
资助金额:45.00万元
-
批准年份:2023
-
负责人:刘开江
-
依托单位:
靶向PARylation介导的DNA损伤修复途径在恶性肿瘤治疗中的作用与分子机制研究
-
批准号:82373145
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:历鹏
-
依托单位:
OBSL1功能缺失导致多指(趾)畸形的分子机制及其临床诊断价值
-
批准号:82372328
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:项盈
-
依托单位:
O6-methyl-dGTP抑制胶质母细胞瘤的作用及分子机制研究
-
批准号:82304565
-
项目类别:青年科学基金项目
-
资助金额:30.00万元
-
批准年份:2023
-
负责人:李瑾
-
依托单位:
Irisin通过整合素调控黄河鲤肌纤维发育的分子机制研究
-
批准号:32303019
-
项目类别:青年科学基金项目
-
资助金额:30.00万元
-
批准年份:2023
-
负责人:职韶阳
-
依托单位:
转录因子LEF1低表达抑制HMGB1致子宫腺肌病患者子宫内膜容受性低下的分子机制
-
批准号:82371704
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:徐步芳
-
依托单位:
上皮细胞黏着结构半桥粒在热激保护中的作用机制研究
-
批准号:31900545
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2019
-
负责人:傅容
-
依托单位: